Industry Briefs: May 21, 2012 - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Industry Briefs: May 21, 2012
A roundup of additional company and people news from pharmaceutical and biopharmaceutical companies, their suppliers, and contract-service providers.


Company News

Avalanche Biotechnologies and Lonza have formed a manufacturing collaboration focused on process development and scale-up efforts for the manufacturing of adeno-associated viral vectors for gene therapy. Read More

GlaxoSmithKline has completed the transaction to increase its ownership in the biopharmaceutical company Theravance. Read More

Lubrizol has formed LifeScience Polymers, a new product line created for the delivery of polymer technologies and solutions to the pharmaceutical and healthcare markets.

Marina Biotech and Girindus Group have formed a development, supply, and commercialization pact for oligonucleotide constructs. Read More

Mitsubishi Tanabe has announced plans to transfer its fine-chemical operations to two companies and withdraw from the fine-chemical industry. Read More

Piramal Healthcare has agreed to acquire Decision Resources Group, a healthcare information management company, for approximately $635 million. Read More

Shimadzu has added a triple quadrupole gas chromatograph mass spectrometer and has also expanded its LC–MS/MS product portfolio. Read More

People News

AMRI has appointed Ian Shott as president of AMRI Europe. Read More

BASi has named David Reynolds as its director of discovery systems. Read More

Camargo has appointed K. Gary Barnette as vice-president of drug development. Read More

Teva’s board of directors has voted to re-elect Phillip Frost as chairman of the board. Read More

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
28%
Oversee medical treatment of patients in the US.
11%
Provide treatment for patients globally.
8%
All of the above.
42%
No government involvement in patient treatment or drug development.
11%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?

Click here